Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. News
Elicio Therapeutics, Inc. Quantitative Score
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Elicio Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Elicio Therapeutics, Inc. Financials
Table Compare
Compare ELTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | ELTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ELTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ELTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ELTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Elicio Therapeutics, Inc. Income
Elicio Therapeutics, Inc. Balance Sheet
Elicio Therapeutics, Inc. Cash Flow
Elicio Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Elicio Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Robert T. Connelly | Chief Executive Officer, President & Director |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research & Development and Chief Medical Officer |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director |
| Ms. Joy Seymour | Vice President & Head of Regulatory Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Robert T. Connelly | Chief Executive Officer, President & Director | Male | 1960 | 943.02K |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research & Development and Chief Medical Officer | 1966 | 721.09K | |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer | 1987 | 648.6K | |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director | 1947 | 48.13K | |
| Ms. Joy Seymour | Vice President & Head of Regulatory Affairs | Female | -- |
Elicio Therapeutics, Inc. Insider Trades
| Date | 3 Jun |
| Name | Chudnovsky Yekaterina |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 103225 |
| Date | 19 May |
| Name | Ashe Carol Gail |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7900 |
| Date | 19 May |
| Name | Nissenson Allen |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7900 |
| Date | 19 May |
| Name | Venkatesan Jay |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7900 |
| Date | 19 May |
| Name | ADAMS JULIAN |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7900 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Jun | Chudnovsky Yekaterina | Director, 10 percent owner | Acquired | A-Award | 103225 |
| 19 May | Ashe Carol Gail | Director | Acquired | A-Award | 7900 |
| 19 May | Nissenson Allen | Director | Acquired | A-Award | 7900 |
| 19 May | Venkatesan Jay | Director | Acquired | A-Award | 7900 |
| 19 May | ADAMS JULIAN | Director | Acquired | A-Award | 7900 |